CAPR - Capricor shares rise on license agreement with Johns Hopkins University

Capricor Therapeutics shares climb ([[CAPR]] +6.3%) after signing an exclusive, worldwide licensing agreement with Johns Hopkins University ((JHU)) to include engineered exosomes for vaccines and therapeutics as part of the company’s exosome technology portfolio.Under the terms of the agreement, Capricor has been granted the exclusive, worldwide rights to JHU’s co-owned interest in intellectual property.The deal allows Capricor to exclusively develop, manufacture and commercialize, with the right to sublicense, IP related to exosome technology for applications across both vaccine and therapeutic areas.Capricor plans to announce further pipeline opportunities and intends to move this technology into the clinic in the near future.

For further details see:

Capricor shares rise on license agreement with Johns Hopkins University